Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of IMVT is 41 and suggests 56% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell